Chemokine receptor-ligand interactions are important to support functioning of both normal and pathological cells. The expression and function of chemokine receptors in epithelial ovarian carcinoma (EOC) is largely unknown. Here, we report that the lymphotactin receptor (XCR1) was expressed in primary and metastatic human epithelial ovarian carcinoma (EOC) specimens and cell lines. In contrast, expression of XCR1 was not detected in the normal ovary or in human normal ovarian surface epithelial cells. Our data indicate that XCL1 and XCL2 are either present in the malignant ascites or expressed by the ovarian carcinoma cells. The addition of lymphotactin (XCL1 and XCL2) stimulated migration and proliferation of XCR1-positive cells.
INTRODUCTION
Epithelial ovarian carcinoma (EOC) has a low incidence compared to other common cancers, with approximately 22,000 women diagnosed with EOC annually. However, it is the leading cause of death from gynecologic malignancies and the fifth leading cause of cancer death in women, as over 14,000 patients succumb to this malignancy each year (1) . EOC is rarely diagnosed during its early stages, when the chance of survival is 90%. Most patients are diagnosed with EOC when micro-and macrometastases are already present (2) . Current treatments are not effective against EOC once it reaches the late metastatic stages. EOC frequently recurs and becomes insensitive to these therapies. Thus, management of the metastatic disease becomes a crucial problem for the treatment of EOC. One possible way to resolve this problem is to target metastasis-specific pathways with novel therapies. Hence, focused identification of novel target pathways and molecules that play a role in metastasis progression could enhance the chances of discovering new and effective therapies. To achieve this goal, we first considered a unique pattern of metastatic dissemination of EOC.
Metastatic EOC colonizes tissues and organs of the peritoneal cavity, whereas the contribution of the hematogenous and lymphagenous spread in forming secondary lesions is minimal (2, 3) .
Malignant cells attach to the mesothelial linings of the peritoneum and the specialized omental structures called "milky spots," and develop into metastatic tumors (2, (4) (5) (6) (7) . This spreading pattern may suggest that the microenvironment of the peritoneal cavity is favorable for homing of EOC metastasis. In fact, peritoneal ascitic fluid is a rich source of growth factors, extracellular matrix proteins, chemokines, and other factors that support and promote peritoneal metastasis (8) (9) (10) .
Chemokine signaling has been extensively associated with homing of metastasis to distant sites (11). Preliminary qPCR array data in our laboratory suggested that the lymphotactin receptor XCR1, one of the members of the chemokine family of GPCRs, was expressed in cell lines of serous EOC. Among chemokine receptors, XCR1 has several unique properties. XCR1 is activated by only two ligands, lymphotactin 1 (XCL1) and lymphotactin 2 (XCL2), which are specific only to this receptor (12) (13) (14) (15) . This high specificity may suggest that the XCL1(2)-XCR1 axis could be a good therapeutic target for processes that depend on these signaling pathways.
XCL1 was first reported to attract CD4+ and CD8+ T lymphocytes and natural killer cells (16) .
Another study showed that XCR1 was expressed by murine CD8+ dendritic cells and their interaction with XCL1-positive CD8+ T-cells regulated cytotoxic immunity (17, 18) . Further, XCL1 induced migration of CD4+ and CD8+ T cells (19) . As recently demonstrated, XCR1-positive thymic dendritic cells were attracted into medulla by XCL1-positive medullary thymic epithelial cells in vivo (20) . The XCL1-XCR1 axis contributes to the progression of various diseases, including rheumatoid arthritis (21), Crohn's disease (22) , and many others (23) . The role of XCL1-XCR1 in cell proliferation, migration, and invasion has been reported in a carcinoma of epithelial origin and an oral squamous carcinoma (24) . The current study investigated whether XCR1 was expressed in human specimens of EOC and whether it may have any functional significance in the progression of this disease. XCR1 expression was found in EOC and supports a hypothesis in which the XCL1(2)-XCR1 axes are active in EOC. XCR1 signaling may support tumor cell properties required for progression toward metastasis, such as migration and proliferation, as well as tumor formation. Our data suggest that XCR1 could be a
MATERIALS AND METHODS
Reagents and Antibodies. Tissue microarrays (TMA) containing specimens of a normal ovary, primary and distant metastatic ovarian carcinomas, and distant metastases from multiple cancer types were obtained from US Biomax (Rockville, MD; Cat## OV208, OV808, MT2081). The cDNA array prepared from specimens of the normal ovary and primary ovarian carcinoma was and survival up to 9 weeks. Some animals were sacrificed earlier (7.7 weeks the earliest) due to their poor health condition, a large volume of ascites, or large tumors visible through the skin.
Animals were sacrificed (on average at 8.5 weeks), dissected, and the abdominal region was examined for tumors. As in most cases it was not possible to determine the margins of the tumors and in many cases the tumors presented as large masses that have fused and encased abdominal organs, measurement of the tumor volume associated with a specific organ was not possible.
Data analysis was performed as "yes" in case when tumor were visible and "no" when no nodules were seen regardless of the size found at a specific abdominal organ and tissue and plotted as a bar graph depicting the percentage of animals bearing metastasis at the indicated tissues and organs. Ascitic fluid was collected and measured. Tumors were collected and paraffin-preserved as described earlier (25) . 
RESULTS

Expression of XCR1 in Normal and
Pathological Ovarian Surface Epithelia. XCR1 is not expressed in the normal ovary (14) . However, the pattern of XCR1 expression during tumorigenic transformation is unknown. Currently, epithelia from both the ovarian surface and the fimbriated edge of the fallopian tube are considered putative precursors of the predominant histotype of serous EOC (26) (27) (28) (29) . We tested for the expression of XCR1 in human specimens and cells from the normal ovary, normal ovarian surface epithelium (NOSE), normal immortalized ovarian surface epithelium, borderline EOC, primary EOC, and metastatic EOC by real-time PCR, immunohistochemistry, flow cytometry, and Western blot. Our examination of the specimens of a noncancerous ovary and primary ovarian carcinoma by real-time PCR demonstrated that none of the noncancerous ovarian tissues expressed XCR1 RNA, whereas 18 of 41 primary stage I -IV EOC specimens were XCR1-positive (Supplementary Table S2 ).
Next, the expression patterns of XCR1 protein was correlated with the RNA. By immunohistochemistry, all cases of the normal ovary containing ovarian surface epithelial cells were XCR1-negative ( Figure 1A , Supplementary Table S3) . Surprisingly, all immortalized ovarian surface epithelial (IOSE) and borderline EOC cell lines were XCR1-positive ( Figure   1B ,C). These data may suggest that XCR1 expression likely occurs early in the process of the tumorigenic transformation for serous EOC that originate from NOSE.
To study the functional significance of XCR1 in EOC, XCR1 expression in a panel of EOC cell lines was determined by Western blot, immunofluorescence, and flow cytometry. EOC cell lines except A2780 were XCR1-positive for XCR1 expression and displayed a strong presence of membranous XCR1 (Figure 2A ,B). Western blot analyses confirmed that IOSE and EOC cell lines expressed XCR1, whereas NOSE did not ( Figure 2C ). Human specimens of primary and metastatic EOC were immunostained for XCR1 and approximately 50% of primary serous EOC cases were XCR1-positive. XCR1 RNA was detected in 45% of the cases (Supplementary Table   S2 ), and 54% of the human tumor samples were immunopositive for XCR1 ( Figure 3 , Supplementary Tables S3 and S4 ). Moreover, 38% of mucinous EOC cases were positive for the XCR1 protein (Additional Table 2 ), and 50% expressed XCR1 RNA (Supplementary Table S2 ).
Furthermore, 38% (n=8) with endometrioid EOC expressed XCR1 RNA (Supplementary Table   S2 ). Finally, the majority (55%) of EOC specimens metastatic to the peritoneal tissues and organs displayed XCR1 protein (n=53) ( Figure 2D , Supplementary Tables S3 and S4 ).
XCL1 and XCL2 Are Present in EOC Ascites and Cell Lines. For XCL1(2)-XCR1-dependent cell
signaling to occur, both the ligand(s) and the receptor must interact. Pro-T cells, T cells, and natural killer cells are the major sources of XCL1 (13) . XCL1 is expressed in the ovary, spleen, small intestine, and colon, which are common sites of primary and metastatic EOC (30) .
Secreted XCL1 binds to the glycosaminoglycans (GAGs) exposed on cell surfaces (31).
Peritoneal ascitic fluid, which commonly accumulates in large volumes in patients with EOC, is a source of a variety of growth factors, metastasis-promoting molecules, and chemokines (8-10).
However, whether this fluid contains soluble, not GAG-bound, XCL1 and XCL2 in unknown.
Thus, the presence and amount of XCL1 and XCL2 ligands was measured in ascitic fluid. To address this question, ascites specimens of malignant EOC (n=3) and borderline gynecologic conditions (n=3) were screened using ELISA. Examination of ascitic fluid samples revealed that XCL2 is significantly more abundant with nanomolar quantities as compared to than XCL1, which is found in only trace amounts (Table 1) . These data could indicate that very little soluble XCL1 is released into the ascitic fluid. Thus, likely sources of XCL1 in the peritoneal cavity include areas in the vicinity of the XCL1-producing cells of the immune system, ovary, and other peritoneal organs as well as cell surface-attached GAGs harboring XCL1 (13, 30, 31) . To further investigate the possible source of XCL1 in EOC, we tested the EOC cell lines IGROV-1, SKOV-3, and A2780 and found that XCL1, but not XCL2, RNA is expressed by these EOC cell lines ( Figure 3A ). XCL1 protein was also detected in total cell lysates of EOC cell lines A2780 and SKOV-3 using ELISA (Table 1) . Interestingly, XCL1 and XCL2 encoding genes are highly homologous and their protein sequences differ by only two amino acids; their transcription is dependent on NFAT (15, 32) . 
XCL1 Induces Proliferation of XCR1-Positive Cell
XCL1 and XCL2 Induce Migration of XCR1-Positive Cell Lines.
Cell migration is essential for metastatic progression. Ovarian carcinoma disseminates locoregionally throughout the peritoneal cavity by shedding malignant cells from the ovary, which is in contrast to the hematogenous or lymphagenous spreading mechanism observed in the majority of solid tumors (34) . Moreover, chemokine/receptor interactions play a role in chemotactic cell migration (11, 33). EOC cells disseminate into the peritoneum during the initial steps of metastatic colonization and support of locoregional migration throughout the cavity occurs from cell migration during the late stages of metastatic colonization. Using animal models, another chemokine network, SDF1-CXCR4, has been shown to contribute to homing of EOC cells to the peritoneum up to 30% (35) . These data provide a proof of principle for the involvement of a chemokine network in the abdominal colonization of EOC. Thus, the ability of EOC cells to engage in XCL1(2)-XCR1 signaling to become more motile was evaluated. To address this question, Transwell cell migration assays were used in which cells were allowed to migrate toward XCL1 and XCL2. The addition of 0.5 nM and 2 nM XCL2 significantly increased cell migration (1.5-and 2.2-fold, respectively) ( Figure 4A ). As XCL2 is not currently commercially available as a purified protein, only non- Figure 4A) . Importantly, the XCR1-negative NOSE cell line, HOSEpiC, did not respond to the addition of exogenous XCL1 ( Figure 4B ). Therefore, XCR1 promotes XCL1-dependent migration.
XCR1 expression in the EOC cell lines IGROV-1 and SKOV-3 was silenced and stimulated to migrate in the presence of human ascites fluid (specimen #2, stage IV serous adenocarcinoma, Table 1 ). Data were compared to cells transfected with a control siRNA. The migration rates were reduced by 60% and 80% in SKOV-3 and IGROV-1, respectively ( Figure 4C) . Notably, the increase in cell migration in the presence of XCL1 was not due to an increase in proliferation because migration assays were conducted within 5 h of treatment, whereas measurable changes in cell proliferation occurred only after 24 h. Western blot analyses demonstrated a significant reduction of XCR1 protein expression levels in SKOV-3 and IGROV-1 transfected with XCR1 siRNA ( Figure 4D ). Overall, these data suggest that the XCL1(2)-XCR1 axis can promote migration of EOC cells. 
XCR1 in Ovarian Carcinoma Cells Facilitates Dissemination of EOC Cells in the Peritoneum.
To expand the in vitro observations and to validate the role of XCR1 in the formation of metastasis, in vivo xenograft experiments were performed wherein ovarian carcinoma SKOV-3 cells were injected intraperitoneally into athymic nude mice. XCR1 was silenced using stable transfection of the GFP-tagged plasmid construct containing XCR1. Several stable clones were created and the one with the lowest residual XCR1 expression (50%, Figure 5A 
XCL1-XCR1 emphasizes the complexity and importance of the chemokine ligand-receptor interactions in the peritoneal milieu of ovarian carcinoma. Together these studies suggest that further examination of other members of the chemokine family for their involvement in pathobiology of ovarian carcinoma may be necessary.
Our data indicate that functional XCR1 is expressed in epithelial ovarian carcinoma. The data suggest that the lymphotactin network in EOC may contribute to the EOC cell migration and proliferation, which are important during metastatic progression. As the lymphotactin receptor is a cell surface receptor of the chemokine family of GPCRs, it represents a potential drug target. 
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